Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 4, 2016, Pages 470-481

  Chen, M J ^a   Liou, J M ^a   Chen, C C ^a   Lee, Y C ^a   Chang, C Y ^b   Wu, J Y ^c   Bair, M J ^d,e   Lin, J T ^f   Wu, M S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e MEIHO UNIVERSITY   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENTIAL THERAPY; SYSTEMATIC REVIEW; THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI;

ADULT; ANTI-INFECTIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84954400746     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13495     Document Type: Article

References (38)

1. Graham DY, Lee YC, Wu MS,. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86 e3.
2. Chey WD, Wong BC,; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
3. Malfertheiner P, Megraud F, O'morain C, et al,. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
4. Ford AC, Forman D, Hunt RH, et al,. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g3174.
5. Yuan Y, Ford AC, Khan KJ, et al,. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
6. Vaira D, Zullo A, Vakil N, et al,. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-63.
7. Gatta L, Vakil N, Vaira D, et al,. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
8. Malfertheiner P, Bazzoli F, Delchier JC, et al,. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
9. Gisbert JP, Calvet X,. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604-17.
10. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al,. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-8 e1.
11. Jafri NS, Hornung CA, Howden CW,. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31.
12. Zullo A, De Francesco V, Hassan C, et al,. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-7.
13. Greenberg ER, Anderson GL, Morgan DR, et al,. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
14. Liou JM, Chen CC, Chen MJ, et al,. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-13.
15. Remes-Troche JM, Rivera GA, Ramos-De la Medina A, et al,. M1119 Sequential Therapy vs. Standard Triple Therapy as Treatment of Helicobacter pylori Infection. A Prospective, Randomized, Parallel-Group, Open-Label Study in Mexico. Gastroenterology 2010; 138: S-336.
16. Kim YS, Kim SJ, Yoon JH, et al,. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-105.
17. Choi HS, Chun HJ, Park SH, et al,. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18: 2377-82.
18. Wu GL, Lan Y, Zhang XJ,. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication. World Chin J Dig 2011; 19: 3100-3.
19. Harmandar FA, Ustundag Y, Buyukuysal C, et al,. The efficacy of clarithromycin based sequential therapy in eradication of Helicobacter pylori in Turkey. Gut 2012; 61 (Suppl. 3): A443.
20. Liou JM, Chen CC, Chang CY, et al,. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2015; doi: 10.1136/gutjnl-2015-310142 [Epub ahead of print].
21. Nasa M, Choksey A, Phadke A, et al,. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. Indian J Gastroenterol 2013; 32: 392-6.
22. Sarikaya M, Dogan Z, Ergül B, et al,. Functional dyspepsia symptom resolution after Helicobacter pylori eradication with two different regimens. Prz Gastroenterol 2014; 9: 49-52.
23. Rakici H, Akdoʇan RA, Bedir R, et al,. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: patients' compliance and bacterial eradication rates. J Dig Dis 2014; 15: 508-13.
24. Makhlough A, Fakheri H, Farkhani AR, et al,. A comparison between standard triple therapy and sequential therapy on eradication of Helicobacter pylori in uremic patients: a randomized clinical trial. Adv Biomed Res 2014; 3: 248.
25. Alsohaibani F, Al Ashgar H, Al Kahtani K, et al,. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015; 21: 220-5.
26. Ferreccio C, Anderson GL, Morgan DR, et al,. A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in seven latin american populations. Gastroenterology 2011; 140: S137.
27. Park S, Chun HJ, Kim ES, et al,. The 10-day sequential therapy for Helicobacter pylori eradication in Korea: less effective than expected. Gastroenterology 2009; 136: A339-40.
28. Isomoto H, Furusu H, Morikawa T, et al,. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1619-23.
29. Rimbara E, Fischbach LA, Graham DY,. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
30. Vakil N, Megraud F,. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001.
31. Liu KS, Hung IF, Seto WK, et al,. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410-5.
32. Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG,. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013; 48: 652-6.
33. Hsu PI, Chen WC, Tsay FW, et al,. Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter 2014; 19: 74-9.
34. Liou JM, Chen CC, Chen MJ, et al,. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011; 66: 1847-52.
35. Liou JM, Wu MS, Chen CC, et al,. Modified sequential therapy containing levofloxacin versus levofloxacin triple therapy in the second line treatment of Helicobacter pylori: a randomized trial. Clin Gastroenterol Hepatol 2015; 13: 1384.
36. Mégraud F,. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 2013; 4: 541-8.
37. Liou JM, Chang CY, Sheng WH, et al,. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother 2011; 55: 1123-9.
38. Liou JM, Chen CC, Chang CY, et al,.; Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-6.